Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

Merck & Company Inc. is riding a wave of positive sentiment, signaling a potential near and mid-term breakout. As the current ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

A telephone-based intervention resulted in significant weight loss for breast cancer patients with overweight or obesity in a ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

MDMA (Molly, ecstasy) is an empathogen widely used as a club drug that may become a future treatment for PTSD. Many respond well to it.

The AAP published its own vaccine schedule in a break from federal guidance. HHS secretary RFK Jr. took to social media to respond.

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ...

This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug ...

Merck announced a significant regulatory milestone with a Breakthrough Therapy designation for its lung cancer drug. This FDA ...